US Patent 8,546,437: Scope, Claim Set, and U.S. Patent Landscape for Hyperuricemia Treatment Methods Using Formula (III)/(IV) Compounds
US Patent 8,546,437 claims U.S. method-of-treatment coverage for hyperuricemia in humans using specific small-molecule chemistry defined by “formula (III)” and a follow-on “formula (IV)” subset. The claim set is structured as (i) core method claims, (ii) parameterized sub-genera (W=S vs O; halogen and group-specific substitutions), (iii) oral dosing and composition embodiment claims (tablet/capsule with named excipients), and (iv) combination therapy with established gout/hyperuricemia agents (URAT1 inhibitors and xanthine oxidase/xanthine dehydrogenase/xanthine oxidoreductase inhibitors, including allopurinol and febuxostat).
Because the claim language you provided is method-centric and heavily parameterized, the scope is broad over genus-defining substitutions and salts/tautomers, but narrower on the core structural “formula (III)/(IV)” definition and any embedded formula definitions you did not fully reproduce.
What are the independent claim 1 and claim 25 actually covering in US 8,546,437?
Claim 1: method of treating hyperuricemia using a formula (III) compound
Claim 1 covers:
- Treating hyperuricemia in a human
- By administering a compound of formula (III) (or a pharmaceutically acceptable salt/ester/tautomer depending on the formula depiction)
- Defined variable constraints:
- X = N
- W = S or O
- R1 = Cl, Br, I, optionally substituted methyl, CF3, CHF2, or CH2F
- R3 and R3′ independently = H or “lower alkyl”
- R2 = a substructure that includes a carbon-carbon double bond (as indicated)
- RP = cyclopropyl
- R8, R9, R10 = H or a pharmaceutically acceptable salt/ester/tautomer thereof
This is a classic “Markush-style” parameter set on a defined scaffold. Practically, claim 1 reads as: if the product is a formula-(III) compound (or salt/ester/tautomer) that meets the variable constraints, using it to treat hyperuricemia in a human by administering it is within scope.
Claim 25: second independent method claim for a formula (IV) compound
Your excerpt shows claim 25 is also a method of treating hyperuricemia by administering a compound of formula (IV) (or salt/ester/tautomer where your excerpt implies it mirrors claim 1). Claim 25’s scope depends on the missing formula-(IV) structural definition. In most patents with parallel (III)/(IV) claims, (IV) typically represents:
- an isomeric/tautomeric or alternative ring-substitution pattern, and/or
- a narrowed region of the genus already partially captured in claim 1.
Without the full formula (IV) definition, the safe reading is that claim 25 is a second method-of-treatment anchor on a different, structurally constrained subset.
How broad are the Markush variables in claim 1 (X=N, W=S/O, R1 halogens and groups)?
X fixed to N
With X set to N, design-arounds that replace that atom with carbon or oxygen are outside the claim 1 definition, regardless of other substituents.
W open to S or O
Claim 1 covers both thio and oxy variants:
- W = S (thio analog)
- W = O (oxo analog)
Dependent claim 2 narrows to W=S.
R1 is a major breadth driver
Claim 1 covers multiple R1 options including:
- Cl, Br, I
- optionally substituted methyl
- CF3
- CHF2
- CH2F
Dependent claims narrow to specific instances you listed, including claim 5: R1=Br, and through claim 6 the R1=Br condition also requires W=S and (by your excerpt) R3 and R3′ H in claim 4.
From a freedom-to-operate lens, this variable scope means a competitor cannot avoid claim 1 coverage by simply swapping Br for Cl, I, or CF3 unless that change also moves the compound outside the formula-(III) structure overall.
R3 and R3′ permit H or lower alkyl
Claim 1 permits:
- each of R3 and R3′ = H or lower alkyl, independently.
Dependent claims 3 and 4 require R3 = H and R3′ = H. That implies the patent distinguishes the fully-unsubstituted pair as a narrower embodiment, but the independent claim already captures the lower-alkyl family.
RP=cylcopropyl and R8/R9/R10=H
These are strong constraints:
- RP fixed to cyclopropyl
- R8/R9/R10 fixed to H (unless the salt/ester/tautomer language expands what you consider those positions in the salt form)
These positions are likely structural “hotspots.” Altering RP or changing those positions would tend to move the compound out of the covered genus.
Which dependent claims narrow claim 1 most (W=S, R3/R3′=H, R1=Br)?
Claim 2 (W=S) and claim 4 (W=S; R3=H; R3′=H)
- Claim 2 restricts claim 1 to thio analogs (W=S).
- Claim 4 adds R3=H and R3′=H.
Claim 3 (R3=H and R3′=H)
Claim 3 narrows to the fully-H lower-alkyl positions while still allowing W=S or O and R1 options.
Claim 5 (R1=Br) and claim 6 (R1=Br; W=S; R3=H and R3′=H)
This nested dependency creates a “specific compound embodiment” claim family layer:
- Claim 5 covers any formula-(III) compound with R1=Br (still under other claim 1 constraints).
- Claim 6 further requires W=S and R3=H and R3′=H.
For enforcement, these dependent claims increase the odds that the patent covers a particular marketed or lead compound candidate even if the generic is close to only some parameters.
How does claim 7 create alternative compound coverage via formula (IV)?
Claim 7 states that in addition to claim 1’s formula-(III) framing, administering a compound of formula (IV) (or salt/ester/tautomer) is covered under the overall method claim set.
This design creates:
- at least two structurally different compound families tied to hyperuricemia treatment, and
- multiple overlapping claim entry points for enforcement depending on which scaffold is commercially used.
What do claim 8–9 cover about salts: full list then sodium salts specifically?
Claim 8
Claim 8 adds salt embodiments, covering:
- ammonium
- primary, secondary, tertiary amines
- lithium, sodium, potassium
- calcium, magnesium, aluminum salts
Claim 9
Claim 9 narrows to:
This is not just a chemistry claim. It matters for litigation and generic design-around because many development programs pick a particular salt form for stability or manufacturability. If the core active is within the formula scope, switching between salt forms can still land within the patent unless the salt form is outside the enumerated group.
What dosage form and excipient-level limits are in the composition method claims (claim 10–20)?
These are not independent “composition of matter” claims as drafted in your excerpt, but they operate as method claims that specify the composition form used for administering.
Oral administration (claim 10)
This can be a key limitation in infringement because parenteral formulations can be argued outside the method claims if all other elements are met but route differs.
Composition embodiment (claim 11)
- administration in a pharmaceutical composition with carrier/excipient/diluent.
Tablet/capsule granularity (claims 12–18)
- Tablet or capsule (claim 12)
- Tablet (claim 13)
- Coated tablet (claim 14)
- Tablet comprises lactose (claim 15)
- Tablet comprises microcrystalline cellulose (claim 16)
- Tablet comprises sodium croscarmellose (claim 17)
- Tablet or capsule comprises gelatin (claim 18)
Manufacturing excipient specifics (claims 19–20)
- Magnesium stearate (claim 19)
- Hydroxypropylcellulose or hydroxypropylmethyl-cellulose (claim 20)
Scope implication: if the branded or infringing product uses a different excipient system or lacks any one of these named components, these dependent claims may not be directly satisfied. Independent method claim 1 still remains, since it does not require any excipient. The excipient-laden claims function as additional coverage paths for specific formulations.
How does the combination therapy layer work in claim 21–24?
Claim 21
The method includes a second agent effective for treatment of gout.
Claim 22
The second agent is one of:
- URAT1 inhibitor
- xanthine oxidase inhibitor
- xanthine dehydrogenase
- xanthine oxidoreductase
- a combination of the foregoing
Claim 23
Second agent includes:
- FYX-051
- allopurinol
- febuxostat
- or combinations
Claim 24
Specifically:
- second agent is allopurinol
Scope implication: combination regimens are directly captured when the formulation is used with the enumerated therapeutic class agents. This is relevant to:
- fixed-dose combination development
- add-on therapy where the product is prescribed alongside allopurinol/febuxostat
- method claims typically survive certain generic design-around attempts focused only on monotherapy products.
What patent landscape issues dominate around a U.S. method-of-treatment patent like 8,546,437?
Core landscape questions that control exclusivity and litigation
- What is the “compound” patent family? Method claims often attach to a broader chemical IP estate that covers synthesis, specific compounds, and compositions.
- Do the dependent excipient claims reflect a specific marketed formulation? If yes, there may be formulation patents or later continuations tied to that exact tablet/capsule design.
- Is there a separate Orange Book listing? If the active is in an NDA/ANDA, Orange Book provides listing-level exclusivity and patent-to-product mapping. A method patent can still be listed with the NDA in some cases.
- Are there likely continuation claims on (III)/(IV) variants? The dual scaffold approach often indicates claim strategy to cover close analogs.
Typical U.S. lifecycle risks for generics
Even without identifying the Orange Book listing or assignee, a method-of-treatment patent like this typically creates:
- Paragraph IV exposure for ANDA filers if their proposed labeling includes hyperuricemia treatment by administering the claimed formula (III)/(IV) compound
- potential settlement leverage for branded manufacturers through “carve-out” labeling negotiations and launch triggers.
How strong is infringement leverage under this claim set (practical claim-coverage mechanics)?
Strong elements
- The claims are formula-anchored and define multiple key scaffold parameters, but include broad substituent sets (not only one R1 or one W).
- The method scope covers salts/esters/tautomers, expanding design-around flexibility.
- The combination layer enumerates common urate-lowering mechanisms (URAT1 inhibition, XO inhibitors, and FYX-051).
- Excipient-specific dependent claims can match a specific commercial formulation if aligned.
Weaker elements for alleged design-around
- Route-specific limitation: claim 10 is oral administration. A non-oral route can avoid dependent claim 10 but not necessarily claim 1.
- Excipient-specific dependent claims: if a competitor uses a different excipient set, claims 15–20 may fail while independent claim 1 remains.
What generic entry risks exist for U.S. 8,546,437?
A generic risk hinges on two facts: (1) whether the generic product’s active is within formula (III)/(IV) variable constraints, and (2) whether its ANDA includes or requires labeling that falls within the claimed method.
Design-around vectors in this kind of claim set:
- Structural change to violate X=N, RP=cyclopropyl, W=S/O, or the fixed positions for R8/R9/R10=H
- Labeling strategy avoiding “treating hyperuricemia in a human” in a manner consistent with claim 1
- Combination-therapy avoidance if the generic is only used as monotherapy and the patented method requires a second gout agent (claim 21 onward)
But: independent claim 1 already covers monotherapy methods (claims 1–20). So even if a generic avoids combination coverage, it still faces the core hyperuricemia method claims.
What formulations are protected by 8,546,437, and how do they map to typical development choices?
Protected formulation categories (from your excerpt)
- Oral tablets and coated tablets
- Tablet excipient pack including:
- lactose
- microcrystalline cellulose
- sodium croscarmellose
- magnesium stearate
- hydroxypropylcellulose or hydroxypropylmethyl-cellulose
- Gelatin capsules/tablets if using gelatin-containing dosage forms
Implications
- If the marketed branded product uses that exact excipient set, the excipient-dependent method claims can support a formulation-level infringement narrative.
- If a generic uses different excipients, it can potentially narrow the infringement case to independent claim 1, which still turns on whether its active is within formula scope.
How to evaluate the patent strength for licensing or investment decisions using this claim architecture
Patent strength signals
- Multi-parameter genus coverage in claim 1 suggests broad chemical control over close analogs.
- Dependent claims target likely “lead embodiments” (R1=Br; W=S; R3/R3′=H).
- Combination therapy claims expand commercial scenario coverage beyond monotherapy.
Patent weakness signals
- The claim set in your excerpt does not show dosage amount ranges, PK/PD ranges, or specific patient subgroups. That can reduce enforceability if the accused product does not match the route and labeling elements.
Key Takeaways
- US Patent 8,546,437 is a method-of-treatment patent for hyperuricemia centered on formula (III) compounds with fixed scaffold anchors (X=N, RP=cyclopropyl, R8/R9/R10=H) and broad substitution tolerance for R1 (Cl/Br/I/methyl/CF3/CHF2/CH2F), W (S or O), and R3/R3′ (H or lower alkyl).
- Coverage extends to salts/ester/tautomers across a broad cation/amine set, including sodium salts.
- Dependent claims add oral dosing and detailed tablet excipient compositions (lactose, microcrystalline cellulose, sodium croscarmellose, magnesium stearate, hydroxypropylcellulose or hydroxypropylmethylcellulose), plus gelatin-containing dosage forms.
- The patent also covers combination gout regimens (URAT1 inhibitors and xanthine oxidase/xanthine dehydrogenase/xanthine oxidoreductase inhibitors, including allopurinol, febuxostat, and FYX-051).
- Overall enforceability leverage is strongest against competitors whose active is within the formula (III)/(IV) genus and whose clinical use and labeling align with hyperuricemia treatment by administration, with formulation-specific dependent claims adding additional hooks when excipient match occurs.
FAQs
1. What is the main structural limitation that competitors must avoid to escape claim 1 coverage?
Avoid altering the core scaffold constraints, especially X=N, RP=cyclopropyl, and the fixed R8/R9/R10=H positions, since these are hardwired in claim 1.
2. Does changing from a sodium salt to a different salt form eliminate infringement risk?
Not if the salt remains within the enumerated pharmaceutically acceptable salt categories in claim 8, including sodium, lithium, potassium, calcium, magnesium, aluminum, and specified amine forms.
3. If a generic product is formulated with different excipients, does it still risk infringement?
Yes, infringement risk remains under the broader independent method claims because excipient-specific limits are concentrated in dependent claims (claims 15–20). Excipient changes mainly affect those dependent claim paths.
4. Are combination therapies with allopurinol covered even if the product is not a fixed-dose combination?
Claim 21 onward covers methods that “further [administer] a second agent,” which can capture add-on use scenarios if the accused regimen meets the claim’s admin elements.
5. Can a non-oral route avoid all claim coverage?
It can avoid dependent claim 10’s “orally” limitation, but independent claim 1 still covers “administering to the human” without specifying oral route, so route changes alone may not eliminate risk.
References (APA)
No sources were provided in the prompt, and no external patent bibliographic identifiers, Orange Book listings, assignees, or prosecution histories were included. Without citation-eligible source material, references cannot be listed.
